Compare Bavarian Nordic A/S with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
DKK 14,893 Million ()
6.00
NA
0.00%
-0.16
18.58%
1.13
Revenue and Profits:
Net Sales:
1,754 Million
(Quarterly Results - Sep 2025)
Net Profit:
1,093 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
582.14%
0%
582.14%
6 Months
1102.01%
0%
1102.01%
1 Year
656.44%
0%
656.44%
2 Years
656.44%
0%
656.44%
3 Years
352.07%
0%
352.07%
4 Years
457.66%
0%
457.66%
5 Years
382.93%
0%
382.93%
Bavarian Nordic A/S for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
29.08%
EBIT Growth (5y)
85.59%
EBIT to Interest (avg)
34.49
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.10
Sales to Capital Employed (avg)
0.35
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.29%
ROCE (avg)
5.55%
ROE (avg)
6.23%
Valuation key factors
Factor
Value
P/E Ratio
6
Industry P/E
Price to Book Value
1.11
EV to EBIT
7.10
EV to EBITDA
4.97
EV to Capital Employed
1.15
EV to Sales
1.71
PEG Ratio
0.06
Dividend Yield
NA
ROCE (Latest)
16.14%
ROE (Latest)
18.58%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Sideways
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bearish
Shareholding Snapshot : Sep 2016
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.29%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
1,754.00
1,653.50
6.08%
Operating Profit (PBDIT) excl Other Income
474.50
543.80
-12.74%
Interest
3.10
3.30
-6.06%
Exceptional Items
39.10
-0.90
4,444.44%
Consolidate Net Profit
1,092.80
362.60
201.38%
Operating Profit Margin (Excl OI)
173.10%
225.60%
-5.25%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 6.08% vs 22.45% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 201.38% vs 65.72% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
5,710.70
7,057.30
-19.08%
Operating Profit (PBDIT) excl Other Income
1,559.20
2,051.30
-23.99%
Interest
13.80
15.00
-8.00%
Exceptional Items
-66.50
-41.30
-61.02%
Consolidate Net Profit
988.00
1,475.20
-33.03%
Operating Profit Margin (Excl OI)
163.60%
212.20%
-4.86%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -19.08% vs 123.98% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -33.03% vs 524.64% in Dec 2023
About Bavarian Nordic A/S 
Bavarian Nordic A/S
Pharmaceuticals & Biotechnology
Bavarian Nordic A/S is a Denmark-based biotechnology company engaged in the development, production and marketing of vaccines for the treatment of cancer and infectious diseases. The Company’s drug pipeline comprises two areas: Cancer Immunotherapy and Infectious Disease. The Cancer Immunotherapy pipeline is focused on: prostate cancer, including PROSTVAC and Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) PRO; breast cancer, providing CV-301 breast and MVA-BN HER2 vaccines; and colorectal cancer, offering CV-301 colon. The Infectious Disease pipeline produces vaccines for a range of illnesses, such as smallpox, anthrax, filoviruses, foot-and-mouth diseases and respiratory syncytial virus. The Company is a parent of Bavarian Nordic GmbH, BN Infectious Diseases A/S, and Bavarian Nordic Inc, among others.
Company Coordinates 
Company Details
Philip Heymans Alle 3 , HELLERUP None : 2900
Registrar Details






